Coacervate Protein Delivery System for Sustained Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current wound healing therapies using recombinant proteins are costly and have short half-lives, requiring frequent dosing and often result in adverse side effects, while existing growth factor treatments for chronic wounds are expensive and ineffective due to high costs and poor clinical usage.
Innovation Solution
A coacervate protein delivery system using natural and synthetic polymers to extend the half-life of proteins, allowing for the simultaneous delivery of multiple growth factors from inexpensive sources like platelet-rich plasma, providing a sustained release over several weeks and reducing the quantity of proteins needed.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If recombinant proteins are used for wound healing therapy, then therapeutic efficacy is improved, but treatment cost increases and half-life decreases
Solution Approach 1:
The patent uses heparin as an intermediary carrier to bind and deliver growth factors to the wound site. The heparin-growth factor complex extends the half-life of recombinant proteins by protecting them from degradation and enabling sustained release, thereby resolving the contradiction between therapeutic efficacy and duration of action.
Solution Approach 2:
The patent changes the physical and chemical parameters of protein delivery by forming complexes with heparin, which alters the pharmacokinetic properties of the growth factors. This complexation extends the half-life from minutes to days, maintaining therapeutic efficacy while reducing dosing frequency.
2Duration of action of moving object
If large doses of proteins are administered to extend half-life, then duration of action is improved, but cost increases and side effects worsen
Solution Approach 1:
Heparin acts as a mediator that enables low-dose protein administration to achieve extended duration of action. The heparin-GF complex provides sustained release at therapeutic sites, reducing the need for large doses and minimizing off-target effects while maintaining prolonged half-life.
3Reliability
If multiple growth factors are delivered simultaneously, then therapeutic efficacy is improved, but device complexity increases
Solution Approach 1:
The patent employs heparin as a universal carrier that can simultaneously bind and deliver multiple different growth factors (VEGF, PDGF, FGF, etc.) through a single delivery system. This multi-functional approach achieves synergistic therapeutic effects while maintaining relative simplicity in the delivery mechanism.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The coacervate system effectively accelerates wound healing by increasing reepithelialization, vascular maturity, and collagen deposition, reducing wound size and improving healing outcomes with fewer doses, while being cost-effective and minimizing side effects.
Implementation Method 1
complex coacervates formed from oppositely charged polymers
Implementation Method 2
complex coacervates formed from oppositely charged polymers can be used to deliver a variety of therapeutic proteins
Implementation Method 3
affinity-based protein delivery system
Data Source
AI summary
Compositions are provided herein comprising a coacervate of a polycationic polymer, a polyanionic polymer, and platelet-rich plasma and/or serum, or a fraction or concentrate thereof. The composition is useful in wound healing. Compositions also are provided that comprise a hydrogel comprising TIMP-3; and a complex of a polycationic polymer, a polyanionic polymer, FGF-2 and SDF-1α embedded in the hydrogel, which is useful in treating a myocardial infarction.